Skip to content


You currently have no items in your basket.


Since 1983, PROGEN has been an established manufacturer and supplier of premium antibodies, in vitro diagnostics, and reagents for the global life science research community. PROGEN’s commitment to quality is underpinned by ISO 13485 certification, and the company’s drive to support and extend existing markets as well as to enter new ones has recently been recognised by German Stifterverband’s "Innovative through Research" award. Lately, PROGEN has expanded its product and service portfolio to include recombinant antibody engineering, antibody phage display technology, density gradient media, and adeno-associated virus (AAV) test kits for gene therapy research.

View All Progen Products

Adeno-Associated Virus Antibodies and ELISA

Adeno-Associated Virus, AAV, a nonpathogenic virus species belonging to the Parvoviridae family. AAV is classified as small (25nm) containing a single-stranded nonenveloped DNA genome. Infection with AAV only occurs with the assistance of other viruses, for example herpesvirus or adenovirus (hence the name adeno-associated virus), causing only a very mild immune response in humans. There are twelve serotypes of human AAV but the number of nonhuman AAVs exceeds 100. AAV2 is the only mammalian DNA virus that is known to integrate in a specific site of the genome.

Immunogenicity is low and the ability to infect dividing as well as non-dividing cells with stable expression make the adeno-associated virus an appealing vector for the application in gene therapy. AAV has successfully been proven as gene therapy vector with the means to attach and enter the target cell, transfer to the nucleus and express the transgene in a stable manner over a sustained period of time. In several clinical trials (e.g. FIX, CFTR, Parkinsons’s, Canavan disease) AAV did not show any serious vector-related adverse effects. Clinically relevant tissues have, however, revealed a diversified susceptibility to AAV infection. The gene transduction with AAV2 vector in muscle, retina, liver and heart resulted in lower gene expression compared to AAV serotypes 1, 5, 8 and 9 transduction in the respective tissues. The challenge of using AAV as gene therapy vector, however, lies in the resistance of some tissues to transduction with the available AAV serotypes.

Target-Organs for AAV

AAV, Adeno-Associated Virus, titration elisa, organs, progen
  1. Xiao, W. et al. Gene therapy vectors based on adeno-associated virus type 1. J. Virol.73, 3994–4003 (1999).
  2. Manfredsson, F. P., Rising, A. C. & Mandel, R. J. AAV9: A potential blood-brain barrier buster. Molecular Therapy17, 403–405 (2009).
  3. Sen, D. et al. Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci. Rep.6, (2013).
  4. Zabner, J. et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol.74, 3852–3858 (2000).
  5. Shen, S., Troupes, A. N., Pulicherla, N. & Asokan, A. Multiple Roles for Sialylated Glycans in Determining the Cardiopulmonary Tropism of Adeno-Associated Virus 4. J. Virol.87, 13206–13213 (2013).
  6. Ai, J. et al. Adeno-associated virus serotype rh.10 displays strong muscle tropism following intraperitoneal delivery. Sci. Rep.7, (2017).
  7. Cheng, B. et al. Development of optimized AAV3 serotype vectors: Mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther.19, 375–384 (2012).
  8. Mingozzi, F. & High, K. A. Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood122, 23–36 (2013).
  9. Richter, M. et al. Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol. Genomics2, 117–27 (2000).
  10. Mori, S. et al. Tissue distribution of cynomolgus adeno-associated viruses AAV10, AAV11, and AAVcy.7 in naturally infected monkeys. Arch. Virol.153, 375–380 (2008).
  11. Guo, Y. et al. A Single Injection of Recombinant Adeno-Associated Virus into the Lumbar Cistern Delivers Transgene Expression Throughout the Whole Spinal Cord. Mol. Neurobiol. (2016).
  12. Schmidt, M. et al. Adeno-Associated Virus Type 12 (AAV12): a Novel AAV Serotype with Sialic Acid- and Heparan Sulfate Proteoglycan-Independent Transduction Activity. J. Virol.82, 1399–1406 (2008).


  • 825KB
  • PDF

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.